Cybin Inc. Launches Global Phase 3 Trial for Breakthrough Depression Treatment, Secures $500M Financing

Cybin Inc. (CYBN) has launched a global Phase 3 trial for its breakthrough depression therapy, CYB003, and secured up to $500 million in financing to accelerate clinical programs and scale up manufacturing. The company has achieved key clinical and regulatory milestones, including approvals from European authorities and the UK's MHRA to initiate its second pivotal Phase 3 study. With a 71% remission rate in prior CYB003 Phase 2 studies, Cybin Inc. is positioning itself as a leader in next-generation treatments for depression and anxiety.